Immunome (IMNM) Competitors $10.59 +0.07 (+0.67%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.78 +0.19 (+1.75%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMNM vs. VKTX, SWTX, AAPG, PTGX, MLTX, HCM, IMVT, KYMR, CRNX, and MORShould you be buying Immunome stock or one of its competitors? The main competitors of Immunome include Viking Therapeutics (VKTX), SpringWorks Therapeutics (SWTX), Ascentage Pharma Group International (AAPG), Protagonist Therapeutics (PTGX), MoonLake Immunotherapeutics (MLTX), HUTCHMED (HCM), Immunovant (IMVT), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry. Immunome vs. Its Competitors Viking Therapeutics SpringWorks Therapeutics Ascentage Pharma Group International Protagonist Therapeutics MoonLake Immunotherapeutics HUTCHMED Immunovant Kymera Therapeutics Crinetics Pharmaceuticals MorphoSys Viking Therapeutics (NASDAQ:VKTX) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk. Does the media favor VKTX or IMNM? In the previous week, Viking Therapeutics had 31 more articles in the media than Immunome. MarketBeat recorded 33 mentions for Viking Therapeutics and 2 mentions for Immunome. Immunome's average media sentiment score of 1.18 beat Viking Therapeutics' score of 0.03 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Immunome 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in VKTX or IMNM? 76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 4.1% of Viking Therapeutics shares are held by insiders. Comparatively, 8.6% of Immunome shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, VKTX or IMNM? Viking Therapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Immunome has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Do analysts recommend VKTX or IMNM? Viking Therapeutics presently has a consensus price target of $86.92, indicating a potential upside of 165.98%. Immunome has a consensus price target of $23.33, indicating a potential upside of 120.33%. Given Viking Therapeutics' higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Immunome.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viking Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00Immunome 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is VKTX or IMNM more profitable? Viking Therapeutics has a net margin of 0.00% compared to Immunome's net margin of -1,875.21%. Viking Therapeutics' return on equity of -19.98% beat Immunome's return on equity.Company Net Margins Return on Equity Return on Assets Viking TherapeuticsN/A -19.98% -19.38% Immunome -1,875.21%-71.65%-60.36% Which has better earnings and valuation, VKTX or IMNM? Viking Therapeutics has higher earnings, but lower revenue than Immunome. Viking Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViking TherapeuticsN/AN/A-$109.96M-$1.53-21.36Immunome$9.04M101.93-$292.96M-$3.18-3.33 SummaryViking Therapeutics beats Immunome on 10 of the 15 factors compared between the two stocks. Get Immunome News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNM vs. The Competition Export to ExcelMetricImmunomeMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$915.37M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-3.3317.6228.6723.80Price / Sales101.93179.18373.9066.65Price / CashN/A41.9535.4557.96Price / Book4.678.508.275.55Net Income-$292.96M-$55.06M$3.24B$259.03M7 Day Performance-2.58%-3.98%-3.69%-4.59%1 Month Performance22.71%9.59%4.33%4.46%1 Year Performance-23.21%6.72%25.95%18.03% Immunome Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNMImmunome2.0688 of 5 stars$10.59+0.7%$23.33+120.3%-29.7%$915.37M$9.04M-3.3340News CoveragePositive NewsGap DownVKTXViking Therapeutics3.7757 of 5 stars$31.94-0.2%$87.15+172.9%-40.2%$3.60BN/A-27.7720Short Interest ↑SWTXSpringWorks TherapeuticsN/A$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230Upcoming EarningsAAPGAscentage Pharma Group InternationalN/A$39.71-1.7%N/AN/A$3.52B$134.35M0.00600PTGXProtagonist Therapeutics2.1351 of 5 stars$55.22-0.5%$66.10+19.7%+41.8%$3.44B$434.43M73.63120Positive NewsUpcoming EarningsMLTXMoonLake Immunotherapeutics2.7013 of 5 stars$53.57+0.9%$74.50+39.1%+25.9%$3.40BN/A-23.292News CoverageUpcoming EarningsHCMHUTCHMED3.2023 of 5 stars$17.74+0.9%$19.00+7.1%-6.5%$3.07B$630.20M0.001,811Positive NewsUpcoming EarningsIMVTImmunovant1.4495 of 5 stars$17.70-1.2%$36.30+105.1%-45.6%$3.06BN/A-6.46120Upcoming EarningsKYMRKymera Therapeutics3.5763 of 5 stars$45.14-2.3%$59.11+31.0%-3.4%$3.01B$47.07M-14.56170News CoveragePositive NewsUpcoming EarningsAnalyst UpgradeAnalyst RevisionCRNXCrinetics Pharmaceuticals3.3269 of 5 stars$30.95-0.5%$69.50+124.6%-46.5%$2.91B$1.04M-8.10210News CoveragePositive NewsUpcoming EarningsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730 Related Companies and Tools Related Companies VKTX Competitors SWTX Competitors AAPG Competitors PTGX Competitors MLTX Competitors HCM Competitors IMVT Competitors KYMR Competitors CRNX Competitors MOR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMNM) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMNM Stock Alerts